Pharmacological Characterization of 5-Substituted 1-[(2,3-dihydro-1-benzofuran-2-yl)methyl]piperazines: Novel Antagonists for the Histamine H-3 and H-4 Receptors with Anti-inflammatory Potential

Detalhes bibliográficos
Autor(a) principal: Correa, Michelle F. [UNIFESP]
Data de Publicação: 2017
Outros Autores: Barbosa, Alefe J. R. [UNIFESP], Teixeira, Larissa B., Duarte, Diego A., Simoes, Sarah C., Parreiras-e-Silva, Lucas T., Balbino, Aleksandro M. [UNIFESP], Landgraf, Richardt G. [UNIFESP], Bouvier, Michel, Costa-Neto, Claudio M., Fernandes, Joao P. S. [UNIFESP]
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Institucional da UNIFESP
Texto Completo: http://dx.doi.org/10.3389/fphar.2017.00825
https://repositorio.unifesp.br/handle/11600/58174
Resumo: The histamine receptors (HRs) are traditional G protein-coupled receptors of extensive therapeutic interest. Recently, H3R and H4R subtypes have been targeted in drug discovery projects for inflammation, asthma, pain, cancer, Parkinson's, and Alzheimer's diseases, which includes searches for dual acting H3R/H4R ligands. In the present work, nine 1-[(2,3-dihydro-1-benzofuran-2-yl) methyl] piperazine (LINS01 series) molecules were synthesized and evaluated as H3R and H4R ligands. Our data show that the N-allyl-substituted compound LINS01004 bears the highest affinity for H3R (pK(i) 6.40), while the chlorinated compound LINS01007 has moderate affinity for H4R (pK(i) 6.06). In addition, BRET assays to assess the functional activity of G(i)1 coupling indicate that all compounds have no intrinsic activity and act as antagonists of these receptors. Drug-likeness assessment indicated these molecules are promising leads for further improvements. In vivo evaluation of compounds LINS01005 and LINS01007 in a mouse model of asthma showed a better anti-inflammatory activity of LINS01007 (3 g/kg) than the previously tested compound LINS01005. This is the first report with functional data of these compounds in HRs, and our results also show the potential of their applications as anti-inflammatory.
id UFSP_9c0f05d8b33d301c604f50148ab68e3a
oai_identifier_str oai:repositorio.unifesp.br/:11600/58174
network_acronym_str UFSP
network_name_str Repositório Institucional da UNIFESP
repository_id_str 3465
spelling Pharmacological Characterization of 5-Substituted 1-[(2,3-dihydro-1-benzofuran-2-yl)methyl]piperazines: Novel Antagonists for the Histamine H-3 and H-4 Receptors with Anti-inflammatory PotentialH3R antagonistsH4R antagonistshistamine receptorsdihydrobenzofuranSARanti-inflammatory activityasthmaThe histamine receptors (HRs) are traditional G protein-coupled receptors of extensive therapeutic interest. Recently, H3R and H4R subtypes have been targeted in drug discovery projects for inflammation, asthma, pain, cancer, Parkinson's, and Alzheimer's diseases, which includes searches for dual acting H3R/H4R ligands. In the present work, nine 1-[(2,3-dihydro-1-benzofuran-2-yl) methyl] piperazine (LINS01 series) molecules were synthesized and evaluated as H3R and H4R ligands. Our data show that the N-allyl-substituted compound LINS01004 bears the highest affinity for H3R (pK(i) 6.40), while the chlorinated compound LINS01007 has moderate affinity for H4R (pK(i) 6.06). In addition, BRET assays to assess the functional activity of G(i)1 coupling indicate that all compounds have no intrinsic activity and act as antagonists of these receptors. Drug-likeness assessment indicated these molecules are promising leads for further improvements. In vivo evaluation of compounds LINS01005 and LINS01007 in a mouse model of asthma showed a better anti-inflammatory activity of LINS01007 (3 g/kg) than the previously tested compound LINS01005. This is the first report with functional data of these compounds in HRs, and our results also show the potential of their applications as anti-inflammatory.Univ Fed Sao Paulo, Dept Ciencias Farmaceut, Diadema, BrazilUniv Sao Paulo, Fac Med Ribeirao Preto, Dept Bioquim & Imunol, Ribeirao Preto, BrazilUniv Montreal, Inst Res Immunol & Canc, Dept Biochem & Mol Med, Montreal, PQ, CanadaUniv Fed Sao Paulo, Dept Ciencias Farmaceut, Diadema, BrazilWeb of ScienceFAPESPCNPqCAPESCanadian Institute for Health ResearchFAPESP: 2013/20479-9FAPESP: 2016/25028-3FAPESP: 2017/02042-3FAPESP: 2012/20148-0FAPESP: 2016/23139-2CNPq: 455411/2014-0Frontiers Media Sa2020-09-01T13:21:17Z2020-09-01T13:21:17Z2017info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersion-application/pdfhttp://dx.doi.org/10.3389/fphar.2017.00825Frontiers In Pharmacology. Lausanne, v. 8, p. -, 2017.10.3389/fphar.2017.00825WOS000415041800005.pdf1663-9812https://repositorio.unifesp.br/handle/11600/58174WOS:000415041800005engFrontiers In PharmacologyLausanneinfo:eu-repo/semantics/openAccessCorrea, Michelle F. [UNIFESP]Barbosa, Alefe J. R. [UNIFESP]Teixeira, Larissa B.Duarte, Diego A.Simoes, Sarah C.Parreiras-e-Silva, Lucas T.Balbino, Aleksandro M. [UNIFESP]Landgraf, Richardt G. [UNIFESP]Bouvier, MichelCosta-Neto, Claudio M.Fernandes, Joao P. S. [UNIFESP]reponame:Repositório Institucional da UNIFESPinstname:Universidade Federal de São Paulo (UNIFESP)instacron:UNIFESP2024-08-01T22:16:04Zoai:repositorio.unifesp.br/:11600/58174Repositório InstitucionalPUBhttp://www.repositorio.unifesp.br/oai/requestbiblioteca.csp@unifesp.bropendoar:34652024-08-01T22:16:04Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP)false
dc.title.none.fl_str_mv Pharmacological Characterization of 5-Substituted 1-[(2,3-dihydro-1-benzofuran-2-yl)methyl]piperazines: Novel Antagonists for the Histamine H-3 and H-4 Receptors with Anti-inflammatory Potential
title Pharmacological Characterization of 5-Substituted 1-[(2,3-dihydro-1-benzofuran-2-yl)methyl]piperazines: Novel Antagonists for the Histamine H-3 and H-4 Receptors with Anti-inflammatory Potential
spellingShingle Pharmacological Characterization of 5-Substituted 1-[(2,3-dihydro-1-benzofuran-2-yl)methyl]piperazines: Novel Antagonists for the Histamine H-3 and H-4 Receptors with Anti-inflammatory Potential
Correa, Michelle F. [UNIFESP]
H3R antagonists
H4R antagonists
histamine receptors
dihydrobenzofuran
SAR
anti-inflammatory activity
asthma
title_short Pharmacological Characterization of 5-Substituted 1-[(2,3-dihydro-1-benzofuran-2-yl)methyl]piperazines: Novel Antagonists for the Histamine H-3 and H-4 Receptors with Anti-inflammatory Potential
title_full Pharmacological Characterization of 5-Substituted 1-[(2,3-dihydro-1-benzofuran-2-yl)methyl]piperazines: Novel Antagonists for the Histamine H-3 and H-4 Receptors with Anti-inflammatory Potential
title_fullStr Pharmacological Characterization of 5-Substituted 1-[(2,3-dihydro-1-benzofuran-2-yl)methyl]piperazines: Novel Antagonists for the Histamine H-3 and H-4 Receptors with Anti-inflammatory Potential
title_full_unstemmed Pharmacological Characterization of 5-Substituted 1-[(2,3-dihydro-1-benzofuran-2-yl)methyl]piperazines: Novel Antagonists for the Histamine H-3 and H-4 Receptors with Anti-inflammatory Potential
title_sort Pharmacological Characterization of 5-Substituted 1-[(2,3-dihydro-1-benzofuran-2-yl)methyl]piperazines: Novel Antagonists for the Histamine H-3 and H-4 Receptors with Anti-inflammatory Potential
author Correa, Michelle F. [UNIFESP]
author_facet Correa, Michelle F. [UNIFESP]
Barbosa, Alefe J. R. [UNIFESP]
Teixeira, Larissa B.
Duarte, Diego A.
Simoes, Sarah C.
Parreiras-e-Silva, Lucas T.
Balbino, Aleksandro M. [UNIFESP]
Landgraf, Richardt G. [UNIFESP]
Bouvier, Michel
Costa-Neto, Claudio M.
Fernandes, Joao P. S. [UNIFESP]
author_role author
author2 Barbosa, Alefe J. R. [UNIFESP]
Teixeira, Larissa B.
Duarte, Diego A.
Simoes, Sarah C.
Parreiras-e-Silva, Lucas T.
Balbino, Aleksandro M. [UNIFESP]
Landgraf, Richardt G. [UNIFESP]
Bouvier, Michel
Costa-Neto, Claudio M.
Fernandes, Joao P. S. [UNIFESP]
author2_role author
author
author
author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Correa, Michelle F. [UNIFESP]
Barbosa, Alefe J. R. [UNIFESP]
Teixeira, Larissa B.
Duarte, Diego A.
Simoes, Sarah C.
Parreiras-e-Silva, Lucas T.
Balbino, Aleksandro M. [UNIFESP]
Landgraf, Richardt G. [UNIFESP]
Bouvier, Michel
Costa-Neto, Claudio M.
Fernandes, Joao P. S. [UNIFESP]
dc.subject.por.fl_str_mv H3R antagonists
H4R antagonists
histamine receptors
dihydrobenzofuran
SAR
anti-inflammatory activity
asthma
topic H3R antagonists
H4R antagonists
histamine receptors
dihydrobenzofuran
SAR
anti-inflammatory activity
asthma
description The histamine receptors (HRs) are traditional G protein-coupled receptors of extensive therapeutic interest. Recently, H3R and H4R subtypes have been targeted in drug discovery projects for inflammation, asthma, pain, cancer, Parkinson's, and Alzheimer's diseases, which includes searches for dual acting H3R/H4R ligands. In the present work, nine 1-[(2,3-dihydro-1-benzofuran-2-yl) methyl] piperazine (LINS01 series) molecules were synthesized and evaluated as H3R and H4R ligands. Our data show that the N-allyl-substituted compound LINS01004 bears the highest affinity for H3R (pK(i) 6.40), while the chlorinated compound LINS01007 has moderate affinity for H4R (pK(i) 6.06). In addition, BRET assays to assess the functional activity of G(i)1 coupling indicate that all compounds have no intrinsic activity and act as antagonists of these receptors. Drug-likeness assessment indicated these molecules are promising leads for further improvements. In vivo evaluation of compounds LINS01005 and LINS01007 in a mouse model of asthma showed a better anti-inflammatory activity of LINS01007 (3 g/kg) than the previously tested compound LINS01005. This is the first report with functional data of these compounds in HRs, and our results also show the potential of their applications as anti-inflammatory.
publishDate 2017
dc.date.none.fl_str_mv 2017
2020-09-01T13:21:17Z
2020-09-01T13:21:17Z
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://dx.doi.org/10.3389/fphar.2017.00825
Frontiers In Pharmacology. Lausanne, v. 8, p. -, 2017.
10.3389/fphar.2017.00825
WOS000415041800005.pdf
1663-9812
https://repositorio.unifesp.br/handle/11600/58174
WOS:000415041800005
url http://dx.doi.org/10.3389/fphar.2017.00825
https://repositorio.unifesp.br/handle/11600/58174
identifier_str_mv Frontiers In Pharmacology. Lausanne, v. 8, p. -, 2017.
10.3389/fphar.2017.00825
WOS000415041800005.pdf
1663-9812
WOS:000415041800005
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv Frontiers In Pharmacology
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv -
application/pdf
dc.coverage.none.fl_str_mv Lausanne
dc.publisher.none.fl_str_mv Frontiers Media Sa
publisher.none.fl_str_mv Frontiers Media Sa
dc.source.none.fl_str_mv reponame:Repositório Institucional da UNIFESP
instname:Universidade Federal de São Paulo (UNIFESP)
instacron:UNIFESP
instname_str Universidade Federal de São Paulo (UNIFESP)
instacron_str UNIFESP
institution UNIFESP
reponame_str Repositório Institucional da UNIFESP
collection Repositório Institucional da UNIFESP
repository.name.fl_str_mv Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP)
repository.mail.fl_str_mv biblioteca.csp@unifesp.br
_version_ 1814268406359130112